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Available online xxxxImmunoglobulin A nephropathy (IgAN) is themost common form of primary glomerulonephritis and is increas-
ingly encountered in pregnancy. The obstetric and renal outcomes of pregnancy are controversial, however.
Women with IgAN are at higher risk of hypertension, preeclampsia and foetal loss; the prognosis is worse for
those who have advanced chronic kidney disease and proteinuria. Here we report the case of a 32-year-old nul-
liparous woman with chronic hypertension who conceived during an active phase of her IgAN, which had been
diagnosed 8 years earlier. Antihypertensive therapies and a low-protein diet were key to her reaching 34 weeks'
gestation with acceptable kidney function. Rupture of membranes occurred at 34 weeks 3 days' gestation and a
healthy boy was delivered the next day. This report aims to provide clinicians with useful information for the
management of patients with IgAN during pregnancy.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Immunoglobulin A nephropathy (IgAN) is themost common formof
primary glomerulonephritis, with a peak incidence in the second and
third decades of life. It is caused by an aberrant glycosylation pattern
of IgA1 and deposition of IgG-IgA immune complexes in the glomerular
mesangium. A broad range of clinicalmanifestations are described, from
minimal proteinuria to the development of end-stage renal disease
(ESRD) [1,2]. The incidence of pregnancy in women with IgAN ranges
from 26.6% to 61% [3]. Most pregnancies occur in patients with an
established diagnosis. Though pregnancy does not seem to affect the
long-term prognosis of patients with normal or slightly compromised
renal function, especially in the absence of gestational hypertension
[4], the risk of adverse obstetric outcomes is higher, with increased peri-
natal mortality (3% to 30%) and incidence of preeclampsia [5].
Proteinuria at the beginning of pregnancy has been reported to be
strongly associated with severe preeclampsia and infant loss [3]. Preg-
nancy is known to be accompanied by physiological hyperfiltration,
whichmay exert a negative effect on kidney function and increase pro-
teinuria in patients with kidney disease [6]. For this reason, controlling
proteinuria in pregnant women is often difficult, especially as most
antiproteinuric agents (i.e., angiotensin-converting enzyme [ACE] in-
hibitors and angiotensin receptor inhibitors) are contraindicated during
pregnancy.s and Gynaecology, Sant'Anna
iglia 3, Torino, Italy.
a88.carosso@tiscali.itFew cases of pregnancyduring an active phase of IgANhave beende-
scribed. Here, we report the case of a 32-year-old nulliparous woman
with chronic hypertension who became pregnant during recurrence of
IgAN diagnosed 8 years earlier.
2. Case Report
The patient first presented with persistent haematuria, fever and
concomitant tonsillitis at the age of 24, for which she was hospitalised.
The renal biopsy was considered insufficient for histological evaluation.
She had proteinuria (protein level 2.6 g/dL), her creatinine levels ranged
between 2.9 and 4.4 mg/dL, and haematuria was present. Based on clin-
ical findings, a diagnosis of IgANwasmade and treatment with steroids
and azathioprine was initiated (100mg a day). Regular follow-up con-
tinued for 4 years without further episodes of haematuria and with
good blood pressure control (b120/80 mmHg).
At age 32 she was again hospitalised for haematuria. Renal ultraso-
nography revealed no kidney stones but moderately hyperechogenic
renal cortex and medulla bilaterally (no previous scans were available
for comparison). The serum creatinine level was 1.3 g/dL, albuminuria
300 mg/dL, and 24-h urine protein excretion 1.2 g. Her blood pressure
was N140/90 mmHg. Given the patient's chronic hypertension, ACE-
inhibitor therapy was started (enalapril 20 mg). When blood and
urine analyses were performed 1 month later, the 24-h urine protein
excretion was 2.2 g, serum creatinine 0.9 g/dL, creatinine clearance 85
mL/min and the red blood cell count was 30/50 cells per high-power
field (HPF). A kidney biopsy was performed.
Microscopical analysis (Fig. 1 A–D) of periodic acid Schiff (PAS)- and
trichrome-stained sections showed glomeruli with Bowman's spaces
Fig. 1. (A) Segmental endocapillary proliferation (PAS stained section, 40×) (B) focal area of glomerular sclerosis (PAS stained section, 40×) (C) fibrinoid necrosis (trichrome stained
section, 40×) (D) fibrinoid necrosis (PTAH stained section, 40×).
Table 1
Kidney function and blood pressure up to 20weeks' gestation.
Parameter 6
weeks
7
weeks
+6
days
9
weeks
+5
days
12
weeks
16
weeks
18
weeks
20
weeks
SBP/DBP 115/60 115/60 120/80 120/60 N140/90 140/90 140/90
SCr 1.1
mg/dL
0.9
mg/dL
0.9
mg/dL
0.8
mg/dL
0.8
mg/dL
0.8
mg/dL
0.8
mg/dL
24-h CrCl 72a
mL/min
66a
mL/min
97a
mL/min
126a
mL/min
– – 172a
mL/min
24-h uP 1.8 g 1.1 g 1.6 g 1.4 g 0.9 g 0.9 g 1.1 g
RBC/HPF 5–10 10–15 N40 2–5 2–5 2–5
SCr denotes serum creatinine; 24-h CrCl 24-h creatinine clearance; 24-h uP 24-h urine
protein excretion; RBC/HPF red blood cells/high-power field; SBP systolic blood pressure;
DBP diastolic blood pressure.
a Corrected per 1.73m2.
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capillary loops. In some segments, the capillaries were occluded by leu-
kocytes or inflammatory cells (endocapillary proliferative glomerulone-
phritis) or showed fibrinoid necrosis and either segmental or global
sclerosis. Specific stains (phosphotungstic acid haematoxylin [PTAH]
and acid fuchsin orange G [AFOG]) highlighted deposits in the
mesangial areas. Immunofluorescence revealed specific IgA and C3 de-
posits in the mesangial areas.
The diagnosis of IgAN was confirmed. Given the presence of active
lesions and 24-h urine protein excretion N1 g, steroid therapy with in-
travenous methylprednisolone (1 g for 3 consecutive days followed by
prednisone 0.5 mg/kg every other day) as described by Pozzi et al. [7]
was initially planned. After taking the first dose of methylprednisolone,
however, the patient tested positive on a self-administered urinary
pregnancy test. Enalapril therapy was therefore immediately
discontinued.
At 6 weeks' gestation, the patient's body weight was 60 kg, blood
pressure 115/60 mmHg, serum creatinine level 1.1 mg/dL, 24-h creati-
nine clearance 70.6 mL/min and 24-h urine protein excretion 1.88 g.
The patient stated she would continue the pregnancy. The steroid
pulse regimen was discontinued. Treatment with prednisone 25 mg,
omeprazole 20mg, folic acid 5 mg, calcium500mg, omega 3 integrators
daily, and supplementation with cholecalciferol (vitamin D3) (100,000
UI 25 drops weekly) was initiated. The patient checked her blood pres-
sure daily and returned to the outpatient clinic every 2 weeks for blood
and urine analysis.
At 16 weeks' gestation, 24-h Holter monitoring revealed an increase
in blood pressure (N140/90 mmHg). Methyldopa (500 mg twice daily)
was started and nifedipine (30 mg/day) added at 26 weeks' gestation
due to the patient's elevated blood pressure. Antihypertensive treat-
ment remained unchanged till delivery. Kidney function was closely
monitored every 2 weeks for changes in serum creatinine and total
24-h urine protein excretion (Tables 1 and 2).
During the first 18 weeks of pregnancy, kidney function was stable,
with a progressive decrease in serum creatinine to 0.8 mg/dL. An in-
crease in 24-h urine protein excretion was observed starting at 20
weeks' gestation, with a peak of 1.8 g at 26 weeks, together with ele-
vated blood pressure. Besides adjusting antihypertensive therapy, a
low-protein diet supplemented with alpha-keto analogues and aminoacids was introduced to reduce animal-derived protein intake. The
diet provided limited quantities (0.6 to 0.8 g/kg/day) and types of pro-
tein (plant-based diet, except for milk, yoghurt and butter), without
any further restrictions and one to three unrestricted meals per week.
For this regimen, the intake of any food of animal origin was discour-
aged, whereas plant-derived foodswere allowed. To avoid excessive in-
take of sugar, the consumption of fruits in moderation was permitted,
and to avoid excessive weight gain the patient was advised to limit
the amount of food for the unrestricted meals. Supplements (Alfa-
Kappa or Ketosteril) were prescribed (one tablet per 8–10 kg of body
weight per day). Under this dietary regimen, 24-h urine protein excre-
tion was successfully maintained at b1 g until delivery.
The patient remained asymptomatic during pregnancy, except at 24
weeks, when she started to show side-effects of corticosteroid therapy
(increased blood pressure, weight gain, lunaris facies). Gestational dia-
betes was excluded by oral glucose tolerance testing (OGTT), and the
prednisone dosage was reduced to 25/12.5 mg daily. An iron supple-
ment was added to her dietary regimen due to persistently low
haemoglobin values (10.6 g/dL). Ultrasoundmonitoring of foetal devel-
opment was performed every 4 weeks. No major malformations were
reported. Amniotic fluid, biometry and Doppler flowmetry of the uter-
ine arteries and umbilical arteries were normal.
Table 2
Kidney function and blood pressure between 22 weeks' gestation and delivery at 34
weeks.
Parameter 22
weeks
24
weeks
26 weeks 28
weeks
30
weeks
32
weeks
34
weeks
SBP/DBP 130/80 130/85 N140/90 130/65 120/55 115/70 130/80
SCr 1.1
mg/dL
0.8
mg/dL
0.8 mg/dL 0.8
mg/dL
0.8
mg/dL
0.8
mg/dL
0.8
mg/dL
24-h CrCl – – 179a
mL/min
– – – –
24-h uP 0.8 g 1 g 1.8 g 0.5 g 0.7 g 0.6 g 0.7 g
RBC/HPF 10–20 2–5 absent 2–5 5–10 2–5 2–5
SCr denotes serum creatinine; 24-h CrCl 24-h creatinine clearance; 24-h uP 24-h urine
protein excretion; RBC/HPF red blood cells/high-power field.
a corrected per 1.73m2.
3A. Carosso et al. / Case Reports in Women's Health xxx (2018) e00074At 32 weeks' gestation, the patient showed early signs of preterm la-
bour. Routine obstetric examination revealed reduced cervical length,
with initial cervical dilatation (approximately 1 cm). Ultrasound vaginal
cervicometry showed a cervical length of 18.8 mm; an Arabin pessary
was inserted. At 34 weeks and 3 days' gestation, preterm premature
rupture ofmembranes (PPROM) occurred. The patientwas hospitalised,
received prophylaxis for foetal respiratory distress syndrome (12 mg of
betamethasone repeated after 24 h) and antibiotic therapy. The next
day a healthy male infant weighing 2660 g was delivered; the Apgar
score was 9 at 1 and 5min.
Ten days later, maternal renal function stabilised, with 24-h urine
protein excretion 1 g and serum creatinine 0.9 mg/dL. The patient
chose to discontinue breastfeeding. Her blood pressure was N140/100
mmHg. Methyldopa was replaced by enalapril 20 mg and prednisone
was tapered over 15 days until total discontinuation. Her blood pressure
was optimised to target levels (b140/90mmHg) over 3 weeks. About 6
months later, renal function was stable. Blood and urine analysis
showed 24-h urine protein excretion was 1.2 g, creatinine clearance
102 mL/min and red blood cell (RBC) count 3–5 RBC/HPF.
3. Discussion
Most large published series have included patients with a history of
IgAN and excluded those with active disease. Different from a previ-
ously described case [8], this is the first report of pregnancy in an active
phase of IgAN in a CKD patient with chronic hypertension. Our case re-
port may provide useful information for clinicians (e.g., obstetricians,
nephrologists) in the management of IgAN patients who become preg-
nant during re-activation of their disease.
Whilst the optimal management of IgAN remains uncertain, cortico-
steroid therapymay lower the risk of progression of kidney disease. Ev-
idence on the treatment effects of other immunosuppressive agents is
controversial [9]; their addition to therapy offers a potentially useful op-
tion in selected patients with a rapidly progressive clinical course [10].
We may speculate that administration of combined steroid/azathio-
prine therapy to the present patient after her initial hospitalization
(not at our institution), in the absence of histological diagnosis, was
motivated by rapidly progressive glomerulonephritis. Other studies
suggest, however, that adding low-dose azathioprine or cyclophospha-
mide to corticosteroids does not give additional benefit to patients with
IgAN [11,12]. Furthermore, immunosuppressive agents are not usually
recommended in IgAN patients, except for those with crescentic IgAN
with rapidly deteriorating kidney function.
In our patient the urine protein loss was N1 g per day, the serum cre-
atinine level was 1.3–0.9 g/dL and the histological sample showed ac-
tive lesions without crescents. Consistent with Italian national
guidelines and Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines, she was treated with a combination of corticosteroids and
antihypertensives [7,13]. Unexpectedly, she becamepregnantwhilst re-
ceiving high-dose steroid therapy plus an ACE inhibitor, which iscontraindicated during pregnancy due to the high risk of foetal toxicity
and major congenital malformations.
The impact of IgAN onmaternal and foetal outcome is controversial.
A decline in kidney function, worse in advanced chronic kidney disease
(CKD) [3,4], and a higher risk of superimposed preeclampsia (SPE) have
been reported [5,14]. In their multicentre study on pregnancy and pro-
gression of IgAN, Limardo et al. reported a decline in kidney function in
both the pregnancy and the non-pregnancy group, with initial protein-
uria predicting a faster decrease [4]. Furthermore, pregnancies among
patients with CKD stages 3 to 4 (estimated glomerular filtration rate
[eGFR] b 60 mL/min), but not CKD stages 1 to 2, were associated with
faster eGFR decline and an increased incidence of progression events
[3]. Our patient became pregnant during an active phase of IgAN, as doc-
umented by renal biopsy (Fig. 1), and she could be categorized as having
CKD stage 2 (eGFR 60–89 mL/min/1.73 m2) according to KDIGO
guidelines.
The incidence of new-onset hypertension in normotensive women
with IgAN prior to conception has not been associated with pregnancy
[4]. Though this conclusion was reached in a study with one of the larg-
est samples worldwide, such an event cannot be completely excluded.
For example, an analysis of 12 Saudi women with well-controlled
blood pressure prior to conception found that all of them required treat-
ment for hypertension during pregnancy [5].
Our patient had chronic hypertension and showed progressive
worsening of blood pressure starting from 16 weeks' gestation. Treat-
ment with methyldopa 500 mg twice daily and nifedipine 30 mg
once daily was administered, since patients with IgAN and chronic hy-
pertension may, in fact, need aggressive treatment to control blood
pressure. Such an approach, combined with the introduction of a low-
protein diet, was effective in controlling 24-h urine protein excretion,
which was reduced from 1.8 g to 0.5 g between 26 and 28 weeks'
gestation.
Due to the increased risk of teratogenicity, administration of ACE in-
hibitors and angiotensin receptor inhibitors is contraindicated during
pregnancy. Growing evidence supports the option of a low-protein
diet for CKD patients since it has the potential advantages of controlling
proteinuria and hyperfiltration.We counselled our patient on taking up
a moderately protein-restricted “vegan-vegetarian diet”, as previously
described by Attini et al., based on a protein intake of 0.6–0.8
g/kg/day, with one to three unrestrictedmeals per week (limited in un-
saturated fats and short-chain sugars) and no specific restriction on salt,
potassium or phosphate intake [15]. Poor pregnancy outcomes
(e.g., small for gestational age and/or delivery before the 28th week)
seem to be reduced in singletons fromon-dietmothers, probably conse-
quent to an improvement in the uteroplacental circulation. This could
result from a decrease in so-called “vaso-toxic” elements and an in-
crease in “vaso-protective” factors. Redmeat consumption, which is as-
sociated with an increase in oxidative stress, is reduced; conversely,
higher vegetable intake may protect against endothelial dysfunction
[16].
A recent systematic review failed to find a consistent association be-
tween maternal vegetarian diet and newborn birth weight. Despite the
lack of randomized studies powered to distinguish the effects of diet
from confounding factors, vegan-vegetarian diets may be considered
safe in pregnancy [17]. In this regard, the American Dietetic Association
stated that “well-planned vegetarian diets are appropriate for individ-
uals during all stages of the lifecycle, including pregnancy, lactation, in-
fancy, childhood” [18]. To date, no studies have reported an increased
risk of adverse pregnancy outcomes, except for an unexplained and un-
confirmed report of a higher incidence of hypospadias in the children of
vegan mothers [19]. Vegetarian diets may lack some nutrients that are
essential during gestation (e.g., fatty acids, vitamin B-12, iron, zinc,
and iodine) and possibly affect the baby's health. To avoid the develop-
ment of dietary deficiencies, we regularly monitored iron, vitamin B12
and 25-OH vitamin D status; vitamins and iron supplements were
added on the basis of blood chemistry results.
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workload on the nephrons, and it did in fact lead to a 24-h urine protein
excretion under 1 g from 26weeks till delivery. To our knowledge, this
is the first time in which such an approach has been applied to a preg-
nant woman with IgAN.
Renal function, measured as 24-h creatinine clearance, improved
from 72 mL/min to 96 mL/min (corrected per 1.73 m2) at 6 and 30
weeks' gestation, respectively. This increase is expected during preg-
nancy. Though renal function was not normal at the beginning of her
pregnancy, it remained acceptable throughout. Progressive improve-
mentwas observed from 7 to 26 weeks' gestation,with a peak 24-h cre-
atinine clearance of 179 mL/min.
Recently, infant loss has been closely associated with CKD stages:
19%, 23% and 45% in stages 1, 2 and 3 to 4, respectively [3]. CKD
poses a challenge for managing pregnancy, from the early stages. In-
deed, the rates of caesarean section, preterm birth and neonatal inten-
sive care are higher than normal even at CKD stage 1. Hypertension
and proteinuria are confirmed as independent risk factors. Preconcep-
tion counselling and strict follow-up are advisable, even when renal
function appears to be maintained at the beginning of pregnancy
[20,21].
Despite the impact of CKD onpregnancy outcomes, conception is not
contraindicated in patients with IgAN and CKD stages 1 to 2, whereas
pregnancy in CKD stages 3 and 4 needs to be carefully considered [3]. In-
deed, severe preeclampsia has been correlated with advanced CKD
stages and proteinuria at the beginning of and during pregnancy is a sig-
nificant risk factor for adverse outcomes. Proteinuria at conception has
been independently associated with a faster decline in postnatal mater-
nal eGFR. A reduction in urine protein levels (N 30%) prior to pregnancy
is thus desirable in order to preserve kidney function [22]. Because the
pregnancy was unexpected in our patient, it was impossible to reach
this target and baseline 24-h urine protein loss was approximately 2 g
before conception.
Our patient did not develop severe preeclampsia, though early signs
of preterm labour were apparent at 32 weeks and PPROM occurred at
34 weeks. NICE guidelines consider women with a cervical length N15
mm at 30 weeks or more of gestational age to be at low risk of preterm
birth [23]. In our patient, the cervical length was 18mm and the dilata-
tion was 10mm at 32 weeks. After extensive discussion we decided to
insert an Arabin pessary to delay the birth, possibly for a few weeks, al-
though evidence for the benefits of pessary use at this gestational age is
lacking. Among women who had asymptomatic singleton pregnancies
and short transvaginal cervical length at 18 to 24 weeks, the use of cer-
vical pessary, compared with no pessary, was associated with a lower
rate of spontaneous preterm birth [24]. Nonetheless, the effectiveness
of a cervical pessary for preventing spontaneous preterm birth remains
debated [25] [26]. Our approach should be considered experimental be-
cause no data on pessary use at an advanced gestational age are cur-
rently available. Moreover, the risk of preterm labour and PPROM in
IgAN patients has not been reported.
Womenwith PPROMhave been noted to havemixed, abnormal vag-
inal microbiota [27]. Frequent causes of PPROM, such as urinary or
cervicovaginal infections, were excluded by culture in the present
case, but altered vaginal microbiota cannot be ruled out. Non-culture
characterization of microbial communities by means of next-
generation sequencing techniques, such as 16S ribosomal RNA (16S
rRNA) gene sequencing, provides a much better understanding of vagi-
nal microbial communities, whereas culture-based techniques vastly
underestimate microbiome diversity [28]. Furthermore, there is emerg-
ing evidence that the diversity of vaginal microbiota during pregnancy
correlates with preterm birth [29,30].Whilst the effect of corticosteroid
administration starting from early pregnancy on vaginal microbiota has
never been explored, vegetarian diet has been associated with a differ-
ent gut microbiome in early pregnancy, but the effects on the vaginal
microbiota are unknown [31]. Further studies are needed to explore
the possible impact of steroid treatments or alternative diets on vaginalmicrobiota in pregnancy, especially when these approaches are used to
treat chronic conditions such as IgAN or other nephropathies.
In conclusion, pregnancy in patients with recurrent IgAN and stage 1
or 2 CKD is not contraindicated if hypertension and renal insufficiency
are controlled adequately. Close monitoring of renal function, blood
pressure, genitourinary infections and foetal conditions is warranted
to minimize the risk of hypertension, preeclampsia, preterm delivery
and foetal loss.
Whilst therapy with high-dose steroids and ACE inhibitors in early
pregnancy does not constitute an absolute contraindication to continue
the pregnancy, the drugs must be discontinued as soon as possible. Pre-
vention of proteinuria before and during pregnancy is strongly recom-
mended, as it is one of the main risk factors for adverse outcomes.
Pregnancy does not appear to be associated with a faster decline in
renal function in these patients. Renal adaptation to pregnancy could re-
sult in a moderate improvement in 24-h creatinine clearance, at least in
patients with recurrent IgAN in stage 1 or 2 CKD.
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